chronic advanced heart failure with reduced ejection fraction (HFrEF) research hub

Randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of 2 dose levels of the oral ghrelin receptor agonist AC01 over 12 weeks in patients with chronic advanced heart failure with reduced ejection fraction (HFrEF)

This study tests a new daily tablet called AC01 for people with long-term heart failure. Researchers want to see if this medicine can help the heart pump blood more effectively. Participants take either the real medicine or a dummy tablet for 12 weeks while doctors monitor their heart health.